Commission Delegated Regulation (EU) 2024/2564 of 19 June 2024 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances

Article 1

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . It shall apply from 1 May 2026 However, substances and mixtures may be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation from the date of entry into force of this Regulation.

Supplementary provisions

ANNEXSupplementary provisions

ANNEX Part 3, Table 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (1) the following entries are inserted following the consecutive order of the index numbers corresponding to each entry: Index No Chemical Name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘005-022-00-4 perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O 2 )), sodium salt, monohydrate [3] sodium peroxoborate [4] sodium perborate [5] 234-390-0 [1] 234-390-0 [2] - [3] - [4] 239-172-9 [5] 11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] - [4] 15120-21-5 [5] Ox. Sol. 3 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 H272 H360FD H331 H302 H335 H318 GHS03 GHS08 GHS06 GHS05 Dgr H272 H360FD H331 H302 H335 H318 inhalation: ATE = 0,75 mg/L (dusts or mists) oral: ATE = 890 mg/kg bw Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % 11’ ‘005-023-00-X perboric acid (H 3 BO 2 (O 2 )), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O 2 )), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] 239-172-9 [1] 234-390-0 [2] - [3] - [4] 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] - [4] Repr. 1B Acute Tox. 4 STOT SE 3 Eye Dam. 1 H360FD H332 H335 H318 GHS08 GHS05 GHS07 Dgr H360FD H332 H335 H318 inhalation: ATE = 1,2 mg/L (dusts or mists) Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % 11’ ‘005-024-00-5 sodium peroxometaborate 231-556-4 7632-04-4 Ox. Sol. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 H272 H360FD H331 H302 H335 H318 GHS03 GHS08 GHS06 GHS05 Dgr H272 H360FD H331 H302 H335 H318 inhalation: ATE = 0,62 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % 11’ ‘006-104-00-2 multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T — — Carc. 1B STOT RE 1 H350i H372 (lung)(inhalation) GHS08 Dgr H350i H372 (lung)(inhalation) STOT RE 1; H372: C ≥ 1 %; STOT RE 2; H373: 0,1 % ≤ C < 1 %’ ‘029-026-00-0 copper [specific surface area > 0,67 mm 2 /mg] 231-159-6 7440-50-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10 M = 1’ ‘047-004-00-9 silver massive: [particle diameter ≥ 1 mm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 H361f H373 (nervous system) GHS08 Wng H361f H373 (nervous system)’ ‘047-005-00-4 silver powder: [particle diameter > 100 nm < 1 mm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 (nervous system) H400 H410 GHS08 GHS09 Wng H361f H373 (nervous system) H410 M = 10 M = 10’ ‘047-006-00-X silver nano: [particle diameter > 1 nm ≤ 100 nm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 (nervous system) H400 H410 GHS08 GHS09 Wng H361f H373 (nervous system) H410 M = 1 000 M = 1 000 ’ ‘603-247-00-8 reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol — — Repr. 1B H360Df GHS08 Dgr H360Df’ ‘605-042-00-9 α-methyl-1,3-benzodioxole-5-propionaldehyde [1] ( S )-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2 S )-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] ( R )-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2 R )-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3] 214-881-6 [1] - [2] - [3] 1205-17-0 [1] 737776-68-0 [2] 737776-59-9 [3] Skin Sens. 1B H317 GHS07 Wng H317’ ‘605-043-00-4 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16] 268-264-1 [1] 252-395-6 [2] - [3] 268-263-6 [4] 267-186-5 [5] 253-139-6 [6] - [7] 248-742-6 [8] 272-113-5 [9] 276-055-1 [10] - [11] - [12] 215-833-7 [13] 215-638-7 [14] 266-810-3 [15] - [16] 68039-49-6 [1] 35145-02-9 [2] 6975-94-6 [3] 68039-48-5 [4] 67801-65-4 [5] 36635-35-5 [6] - [7] 27939-60-2 [8] 68737-61-1 [9] 71832-78-5 [10] 40702-26-9 [11] 1726-47-2 [12] 1423-46-7 [13] 1335-66-6 [14] 67634-07-5 [15] 6754-27-4 [16] Skin Sens. 1 H317 GHS07 Wng H317’ ‘606-156-00-1 acetone oxime 204-820-1 127-06-0 Carc. 1B Acute Tox. 4 STOT SE 3 STOT RE 2 Eye Dam. 1 Skin Sens. 1 H350 H312 H336 H373 (blood system) H318 H317 GHS08 GHS07 GHS05 Dgr H350 H312 H336 H373 (blood system) H318 H317 dermal: ATE = 1 100 mg/kg bw’ ‘606-157-00-7 (3 E )-dec-3-en-2-one — 18402-84-1 Acute Tox. 4 Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 2 H332 H304 H315 H411 GHS07 GHS08 GHS09 Dgr H332 H304 H315 H411 EUH071 inhalation: ATE = 1,5 mg/L (dusts or mists)’ ‘606-158-00-2 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one 438-340-0 119344-86-4 Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 H360Df H400 H410 GHS08 GHS09 Dgr H360Df H410 M = 1 M = 1’ ‘607-770-00-2 2,3-epoxypropyl neodecanoate 247-979-2 26761-45-5 Muta. 2 Skin Sens. 1A H341 H317 GHS08 GHS07 Wng H341 H317 Skin Sens. 1A; H317: C ≥ 0,001 %’ ‘607-771-00-8 benthiavalicarb-isopropyl (ISO); isopropyl [( S )-1-{[( R )-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate — 177406-68-7 Carc. 1B Repr. 2 Skin Sens. 1 Aquatic Chronic 2 H350 H361fd H317 H411 GHS08 GHS07 GHS09 Dgr H350 H361fd H317 H411’ ‘607-772-00-3 hexyl salicylate 228-408-6 6259-76-3 Repr. 2 Skin Sens. 1 H361d H317 GHS08 GHS07 Wng H361d H317’ ‘607-773-00-9 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate 219-207-4 2386-87-0 Muta. 2 STOT RE 2 Skin Sens. 1 H341 H373 (nasal cavity) H317 GHS08 GHS07 Wng H341 H373 (nasal cavity) H317’ ‘607-774-00-4 tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3] 241-164-5 [1] - [2] - [3] 17095-24-8 [1] - [2] 100556-82-9 [3] Resp. Sens. 1A Skin Sens. 1 H334 H317 GHS08 Dgr H334 H317’ ‘607-775-00-X Sodium 3-(allyloxy)-2-hydroxypropanesulphonate 258-004-5 52556-42-0 Repr. 1B Eye Dam. 1 H360F H318 GHS08 GHS05 Dgr H360F H318’ ‘609-074-00-4 1,4-dichloro-2-nitrobenzene 201-923-3 89-61-2 Carc. 1B H350 GHS08 Dgr H350’ ‘611-182-00-1 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol 271-183-4 68516-81-4 Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,001 %’ ‘612-299-00-0 fenpropidin (ISO); ( R , S )-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine — 67306-00-7 Repr. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H400 H410 GHS08 GHS07 GHS05 GHS09 Dgr H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H410 Inhalation: ATE = 1,2 mg/L (dusts or mists) oral: ATE = 1 330 mg/kg bw M = 1 000 M = 10 000 ’ ‘613-350-00-X 1 H -benzotriazole 202-394-1 95-14-7 Aquatic Chronic 2 H411 GHS09 Wng H411’ ‘613-351-00-5 methyl-1 H -benzotriazole 249-596-6 29385-43-1 Aquatic Chronic 2 H411 GHS09 Wng H411’ ‘616-243-00-6 N,N' -methylenediacrylamide 203-750-9 110-26-9 Muta. 1B H340 GHS08 Dgr H340’ ‘617-024-00-8 tert -butyl 2-ethylperoxyhexanoate 221-110-7 3006-82-4 Repr. 1B Skin Sens. 1 H360FD H317 GHS08 GHS07 Dgr H360FD H317’ (2) the entries corresponding to index numbers 005-005-00-1, 016-022-00-9, 016-094-00-1, 029-019-01-X, 601-037-00-0, 604-020-00-6, 605-001-00-5, 607-001-00-0, 607-043-00-X, 607-094-00-8, 607-198-00-3, 607-315-00-8, 607-432-00-4, 613-272-00-6, 616-127-00-5 and 617-008-00-0 are replaced by the following entries respectively: Index No Chemical Name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘005-005-00-1 trimethyl borate 204-468-9 121-43-7 Flam. Liq. 3 Repr. 1B Acute Tox. 4* H226 H360FD H312 GHS02 GHS08 GHS07 Dgr H226 H360FD H312 11’ ‘016-022-00-9 ethanethiol; ethyl mercaptan 200-837-3 75-08-1 Flam. Liq. 1 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H224 H331 H302 H400 H410 GHS02 GHS06 GHS09 Dgr H224 H331 H302 H410 inhalation: ATE = 7,1 mg/L (vapours) oral: ATE = 680 mg/kg bw’ ‘016-094-00-1 sulfur 231-722-6 7704-34-9 Skin Irrit. 2 H315 GHS07 Wng H315’ ‘029-019-01-X copper flakes (coated with aliphatic acid) Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 H302 H319 H400 H410 GHS06 GHS09 Dgr H331 H302 H319 H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 1’ ‘601-037-00-0 n -hexane 203-777-6 110-54-3 Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT SE 3 STOT RE 1 Skin Irrit. 2 Aquatic Chronic 2 H225 H361f*** H304 H336 H372 (nervous system) H315 H411 GHS02 GHS08 GHS07 GHS09 Dgr H225 H361f*** H304 H336 H372 (nervous system) H315 H411’ ‘604-020-00-6 biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl 201-993-5 90-43-7 Carc. 2 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H351 H314 H318 H317 H400 H410 GHS08 GHS05 GHS07 GHS09 Dgr H351 H314 H317 H410 M = 1 M = 1’ ‘605-001-00-5 formaldehyde … % 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1B Skin Sens. 1A H350 H341 H330 H302 H314 H317 GHS08 GHS06 GHS05 Dgr H350 H341 H330 H302 H314 H317 EUH071 inhalation: ATE = 100 ppmV (gases) oral: ATE = 500 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % B, D, F’ ‘607-001-00-0 formic acid … % 200-579-1 64-18-6 Flam. Liq. 3 Met. Corr. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 H226 H290 H331 H302 H314 H318 GHS02 GHS05 GHS06 Dgr H226 H290 H331 H302 H314 EUH071 inhalation: ATE = 7,4 mg/L (vapours) oral: ATE = 500 mg/kg bw Flam. Liq. 3; H226: C > 85 % Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; 314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤ C < 10 % Eye Dam. 1; H318: C ≥ 10 % Eye Irrit. 2; H319: 2 % ≤ C < 10 % B’ ‘607-043-00-X dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid 217-635-6 1918-00-9 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 2 H332 H302 H335 H336 H318 H400 H411 GHS07 GHS05 GHS09 Dgr H332 H302 H335 H336 H318 H410 inhalation: ATE = 4,0 mg/L (dusts or mists) oral: ATE = 1 500 mg/kg bw M = 1’ ‘607-094-00-8 peracetic acid … % 201-186-8 79-21-0 Org. Perox. D Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 H242 H330 H310 H301 H314 H400 H410 GHS02 GHS06 GHS05 GHS09 Dgr H242 H330 H310 H301 H314 H410 EUH071 inhalation: ATE = 0,2 mg/L (dusts or mists) dermal: ATE = 60 mg/kg bw oral: ATE = 80 mg/kg bw STOT SE 3; H335: C ≥ 1 % M = 10 M = 100 B, D, T’ ‘607-198-00-3 propyl 3,4,5-trihydroxybenzoate 204-498-2 121-79-9 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 H410 oral: ATE = 1 700 mg/kg bw M = 1 M = 1’ ‘607-315-00-8 glyphosate (ISO); N -(phosphonomethyl)glycine 213-997-4 1071-83-6 Eye Dam. 1 Aquatic Chronic 2 H318 H411 GHS05 GHS09 Dgr H318 H411’ ‘607-432-00-4 S -metolachlor (ISO); 2-chloro- N -(2-ethyl-6-methylphenyl)- N -[(2 S )-1-methoxypropan-2-yl]acetamide; ( R a S a )-2-chloro- N -(6-ethyl- o -tolyl)- N -[(1 S )-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro- N -(2-ethyl-6-methylphenyl)- N -[(2 S )-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro- N -(2-ethyl-6-methylphenyl)- N -[(2 R )-1-methoxypropan-2-yl]acetamide] — 87392-12-9 Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H317 H410 EUH066 M = 10 M = 10’ ‘613-272-00-6 pyraclostrobin (ISO); methyl N -(2-{[1-(4-chlorophenyl)-1 H -pyrazol-3-yl]oxymethyl}phenyl) N -methoxy carbamate — 175013-18-0 Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H400 H410 GHS08 GHS06 GHS09 Dgr H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H410 inhalation: ATE = 0,58 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw M = 100 M = 100’ ‘616-127-00-5 reaction mass of N,N' -ethane-1,2-diylbis(decanamide) and 12-hydroxy- N -[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N' -ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N' -ethane-1,2-diylbis(decanamide) and 12-hydroxy- N -[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2] 430-050-2 [1] - [2] - [1] - [2] Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 M = 100 M = 10’ ‘617-008-00-0 dibenzoyl peroxide; benzoyl peroxide 202-327-6 94-36-0 Org. Perox. B Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H241 H319 H317 H400 H410 GHS01 GHS02 GHS07 GHS09 Dgr H241 H319 H317 H410 M = 10 M = 10’ (3) the entries corresponding to index numbers 005-017-00-7, 005-017-01-4, 005-018-00-2, 005-018-01-X, 005-019-00-8, 005-019-01-5 and 029-024-00-X are deleted.

Article 1

Article 2

Supplementary provisions

ANNEXSupplementary provisions

What to look at next